Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Accumulated Expenses (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Accumulated Expenses data on record, last reported at $20.9 million in Q3 2023.

  • For Q3 2023, Accumulated Expenses rose 55.08% year-over-year to $20.9 million; the TTM value through Sep 2023 reached $20.9 million, up 55.08%, while the annual FY2022 figure was $14.1 million, 64.8% up from the prior year.
  • Accumulated Expenses reached $20.9 million in Q3 2023 per CGEM's latest filing, up from $15.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $20.9 million in Q3 2023 and bottomed at $4.2 million in Q2 2021.
  • Average Accumulated Expenses over 4 years is $11.2 million, with a median of $11.2 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: surged 181.15% in 2022, then surged 30.5% in 2023.
  • A 4-year view of Accumulated Expenses shows it stood at $4.6 million in 2020, then surged by 84.81% to $8.6 million in 2021, then soared by 64.8% to $14.1 million in 2022, then surged by 48.19% to $20.9 million in 2023.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $20.9 million in Q3 2023, $15.5 million in Q2 2023, and $18.4 million in Q1 2023.